Diligence memo · auto-generated · as of July 3, 2026
Constance Therapeutics, Inc.
Constance Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Constance Therapeutics, Inc. operates in Pharma, based in SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Constance Therapeutics, Inc. has raised $4.7M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.2M on 2018-02-23.
Most recent recorded round closed around 2018-02-23.
Valuation (modeled)modeled
Provath models Constance Therapeutics, Inc. at approximately $132M (range $4.9M–$715M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.72× the median modeled value of Series A Pharma companies in 2016–2018 (14 peers) — value vs value, same stage and era. Within the normal band (72% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 8.4 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 8.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 54% of Pharma peers (310 compared).
Modeled value ranks above 71% of those peers.
Closest niche peers: Qool Therapeutics, Inc., SpringWorks Therapeutics, LLC, Caliber Therapeutics, Inc., Rodin Therapeutics, Inc., SmartPharm Therapeutics, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.